Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Organon |
---|---|
Information provided by: | Organon |
ClinicalTrials.gov Identifier: | NCT00434824 |
In this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone testosterone.
Specifically, we have studied the effects on:
Condition | Intervention | Phase |
---|---|---|
Hypogonadism Androgens |
Drug: Oral testosterone undecanoate (Andriol) Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency |
Enrollment: | 322 |
Study Start Date: | November 2001 |
Study Completion Date: | July 2004 |
Primary Completion Date: | July 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Active Comparator
Oral testosterone undecanoate (Andriol)
|
Drug: Oral testosterone undecanoate (Andriol)
treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
|
Arm 2: Placebo Comparator
Placebo
|
Drug: Placebo
treatment for 12 months with placebo in divided doses
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | NV Organon, part of Schering-Plough Corporation ( Study Director ) |
Study ID Numbers: | 43203 |
Study First Received: | February 12, 2007 |
Last Updated: | August 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00434824 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Testosterone Hypogonadism Gonadal Disorders Endocrine System Diseases |
Methyltestosterone Endocrinopathy Testosterone 17 beta-cypionate |
Anabolic Agents Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs |
Hormones, Hormone Substitutes, and Hormone Antagonists Hormones Pharmacologic Actions Androgens |